A5026474135- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Melanoma and MAPK Pathways
- Cancer Research and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Prostate Cancer Treatment and Research
- MRI in cancer diagnosis
Agostino Gemelli University Polyclinic
2020-2025
Università Cattolica del Sacro Cuore
2020-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Università Campus Bio-Medico
2023
In the last years, theranostics has expanded therapeutic options available for prostate cancer patients. this review, we explore dynamic field and its potential to revolutionize precision medicine cancer. We delve into foundational principles, clinical applications, emerging opportunities, emphasizing synergy between radioligand therapy other systemic treatments. Additionally, address ongoing challenges, including optimizing patient selection, assessing treatment responses, determining role...
BackgroundBoth aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy this setting.MethodsWe launched a multicenter, retrospective, observational study to assess compare clinical efficacy of aflibercept-based as mCRC. Patients KRAS/NRAS/BRAF-wild type KRAS/NRAS mutant tumors were also analyzed separately.Findings348 consecutive...
The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated first-line immunotherapy combinations (TKI plus ICI or ICI). We performed a sub-analysis multicenter retrospective observational (ARON-1 project) involving combinations. Three hundred twenty-nine were enrolled, 244 males 85 females. Median age was 65.5 years. impact on PFS OS observed whole population examined. had correlation neutrophil-to-lymphocyte (NLR), blood...
Immunotherapy combinations with tyrosine-kinase inhibitors (TKIs) and immune checkpoint (ICIs) had significantly improved outcomes of patients mRCC. Predictive prognostic factors are crucial to improve patients' counseling management. The present study aimed externally validate the value a previously developed red cell-based score, including hemoglobin (Hb), mean corpuscular volume (MCV) cell distribution width (RDW), in mRCC treated first-line immunotherapy (TKI plus ICI or ICI). We...
RAS mutations involving codon 61 are rare in metastatic colorectal cancer (mCRC), accounting for only 1–4%, but they have recently been identified with high frequency the circulating tumor DNA (ctDNA) of patients secondary resistance to anti-EGFRs. This retrospective monocentric study aimed investigate clinical phenotype and prognostic performance RAS-mutated mCRC. Fifty mCRC treated at our institution between January 2013 December 2021 were enrolled. Additional datasets wild-type mCRCs (648...
Patients with refractory mCRC rarely undergo third-line or subsequent treatment. This strategy could negatively impact their survival. In this setting, regorafenib (R) and trifluridine/tipiracil (T) are two key new treatment options statistically significant improvements in overall survival (OS), progression-free (PFS), disease control different tolerance profiles. study aimed to retrospectively evaluate the efficacy safety profiles of these agents real-world practice.
There are few molecular markers driving treatment selection in later lines of for advanced colorectal cancer patients. The vast majority patients who progress after first- and second-line therapy undergo chemotherapy regardless data. We aimed to assess the prognostic predictive effects specific RAS mutations on overall survival receiving regorafenib (rego), trifluridine/tipiracil (TFD/TPI), or both. This was a retrospective observational study based data from previous our research network,...
45 Background: Regorafenib (R) and Trifluridine/tipiracil (T) have been shown to prolong survival for patients (pts) with refractory metastatic colorectal cancer (mCRC) but it's date unclear which agent should be administered first. Our analysis aimed compare the efficacy safety profiles of these drugs sequentially in daily clinical practice. Methods: Clinical data pts diagnosed mCRC who received R and/or T between July 2012 March 2022, were retrospectively collected from 12 institutes Lazio...
Background Right- (R) and left-sided (L) metastatic colorectal cancer (mCRC) exhibit different clinical molecular features. Several retrospective analyses showed that survival benefit of anti-EGFR-based therapy is limited to RAS/BRAF wt L-sided mCRC patients. Few data are available about third-line anti-EGFR efficacy according primary tumor site. Methods patients treated with versus regorafenib or trifluridine/tipiracil (R/T) were retrospectively collected. The objective the analysis was...
TPS723 Background: The therapeutic gold standard for muscle invasive bladder cancer (MIBC) is radical cystectomy (RC) preceded by neoadjuvant chemotherapy when appropriate. However, RC a major surgery procedure with 13% rate of severe complication and perioperative mortality about 1.5 - 5 %. Trimodal therapy (TMT) “bladder sparing” option alternative to RC. TMT consists complete transurethral tumor resection (TURBT) followed combination systemic locoregional radiotherapy (RT), the “salvage”...
e15553 Background: Rechallenge with anti-EGFR drugs has recently proven therapeutic activity in a subset of RAS wild type (wt) metastatic colorectal cancer (mCRC) patients who had previously benefited from cetuximab- or panitumumab-based first-line regimen. Regorafenib (R) and Trifluridine/tipiracil (T) have been found to improve survival refractory mCRC. This real-life subgroup analysis focused on treatment R T, sequential not, received prior third-line therapy. Methods: Clinical data...
: Unlike liver metastases, the role of surgery in colorectal cancer lung-limited metastases (CCLLM) is not yet established, and data are still poor. We performed a retrospective analysis to evaluate impact on management CCLLM.
Background: There is ongoing discussion around the optimal course of treatment for metastatic colorectal cancer (mCRC) following second line. Trifluridine/tipiracil (T) and regorafenib (R) have been mainstay therapy in this situation, as they both increased overall survival (OS) comparison to a placebo. Despite paucity evidence, rechallenge also recognized an option practical use. In third-line scenario mCRC, we planned investigate outcomes using (R), with without prior treatment. Materials...
This article describes the main acquisitions of renal cell carcinoma (RCC) management presented during 2023 American Society Clinical Oncology (ASCO) Genitourinary Cancers Symposium. In particular, efficacy adjuvant pembrolizumab in patients with resected at increased risk recurrence was confirmed through a subgroup analysis. metastatic setting, updated analysis CheckMate 9ER study terms overall survival (OS) combination nivolumab plus cabozantinib; note, this advantage clear poor IMDC...
In this article, we describe the main acquisitions of urothelial carcinoma (UC) management reported at 2023 American Society Clinical Oncology Genitourinary Cancers Symposium. A major development year was characterized by confirmation a disease-free survival advantage adjuvant nivolumab for high-risk muscle-invasive after radical resection longer follow-up. metastatic setting, updated analysis IMvigor130 study confirmed failure strategy adding immunotherapy (i.e. atezolizumab) to first-line...
e13641 Background: The management of CRC is complex, particularly in metastatic disease, where it crucial the definition disease burden, assessment radiological response and identification right timing for potential radical surgery or loco-regional treatments. A correct evaluation subsequent choice most appropriate treatment strategy, need, therefore, a MDT involving surgeons, oncologists, radiologists, radiation endoscopists, gastroenterologists pathologists. Based on such considerations,...
Background: The optimal treatment for metastatic colorectal cancer (mCRC) beyond second line is still questioned. Besides the standard of care agents (regorafenib, REG, or trifluridine/tipiracil, FTD/TPI), chemotherapy rechallenge reintroduction (CTr/r) are commonly considered in clinical practice, despite weak supporting evidence. prognostic performance CTr/r, REG and FTD/TPI this setting herein evaluated.Patients methods: PROSERpYNa a multicenter, observational, retrospective study, which...
e15539 Background: Early-onset colorectal cancer (EOCRC), defined as CRC diagnosed among individuals younger than 50 yrs, is becoming a public health issue, with rising incidence reported worldwide. In the US, EOCRC leading cause of cancer-related death males aged 20-49 yrs and second female 40-49 yrs. Italy lacks national registry available data regard mostly northern regions. Fondazione Policlinico Gemelli (FPG) Hospital referral center for (especially middle southern regions), ranking...
3593 Background: Despite rising incidence and mortality reported worldwide for CRC diagnosed in pts aged < 50 yrs, currently early onset metastatic (EOmCRC) are treated as their older counterparts. We aimed to investigate how this specific subgroup is real world. Methods: This an observational, retrospective, monocentric study aiming describe features, management prognosis of EOmCRC. Pts with EOmCRC at our Institution between Apr2002 Dec2022 were included. Applying a descriptive method,...
e15598 Background: Nowadays, RAS mutational status remains a key determinant in mCRC patients’ therapeutic algorithm. Mutations involving codon 61 are rare, accounting for 1-4%, but have been recently identified with high frequency ctDNA of pts secondary resistance to anti-EGFR mAbs, prevalence 50% the Chronos trial. Despite growing clinical relevance these mutations, evidence on clinicopathological features and prognosis harboring mutations is limited relies small retrospective studies. In...